Indefinite Delivery Contract SPE2DR25D1104

Award Date 8/1/25
Last Date to Order 12/31/36
Ultimate Awardee
Not listed
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The Indefinite Delivery Contract (IDC) SPE2DR25D2208 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $999,999,999 contract has a performance period through December 2036 and serves as a vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The IDC encompasses critical medical commodities including...
The Indefinite Delivery Contract (IDC) SPE2DR25D6037 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $999,999,999 contract runs through December 2036 and is for the provision of a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract serves as a prime vehicle for delivering brand-name and generic drugs, specialty...
The Indefinite Delivery Contract (IDC) SPE2DR25D1002, awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, is a single-award contract valued at $9,999,999,999 running through December 31, 2036. This IDC serves as the primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, including specialty medications, brand-name and generic drugs, vaccines, syringes,...
The Indefinite Delivery Contract (IDC) SPE2DR25D7910 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $999,999,999, has a period of performance through December 2026 and is intended to provide worldwide pharmaceutical support to various Department of Defense (DoD) customers, including the Defense Health Agency, the U.S. Coast Guard, and...
The Indefinite Delivery Contract (IDC) SPE2DR25D3002 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for a ceiling value of $999,999,999. The contract provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across...
The Indefinite Delivery Contract (IDC) SPE2DR25D1116 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $999,999,999 IDC has an ultimate completion date of December 31, 2036 and serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The original...
The Indefinite Delivery Contract (IDC) SPE2DR25D6035 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $999,999,999, is a single-award IDC with a period of performance through December 31, 2036. The purpose of this IDC is to establish a Pharmaceutical Prime Vendor Global Program to provide worldwide pharmaceutical support, including...
The Indefinite Delivery Contract (IDC) awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to AmerisourceBergen Drug Corp, valued at $999,999,999, covers the delivery of a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract has a 30-month base period and three 30-month option periods, for a total estimated value of $30.3 billion. The IDC serves as the Pharmaceutical Prime Vendor Global...
The Indefinite Delivery Contract (IDC) SPE2DR25D7062 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,999,999,999 IDC, running through December 2036, is a prime vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The underlying solicitation, known as the...
The Indefinite Delivery Contract (IDC) SPE2DU25D5117 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $999,999,999 and runs through December 2036, serving as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This includes...

The Indefinite Delivery Contract (IDC) SPE2DR25D1104 was awarded by the Defense Logistics Agency (DLA) Troop Support Medical Supply Chain to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract has a $9,999,999,999 ceiling value and runs through December 31, 2036. It serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.

The IDC encompasses critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. It enables efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries. The contract was awarded as part of the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) solicitation, which plans to establish multiple regional contracts with a total estimated value of $30.3 billion. The acquisition aims to ensure resiliency and access to vital pharmaceuticals for the Department of Defense during contingencies or natural disasters.

Generated 6/6/25, 10:05 AM